Successful transatlantic bilateral hand transplant in a young female highly sensitized to HLA class II antigens.
Composite
HLA
Sensitized
Transplant
Vascularized
Journal
Transplant immunology
ISSN: 1878-5492
Titre abrégé: Transpl Immunol
Pays: Netherlands
ID NLM: 9309923
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
15
01
2021
revised:
14
02
2021
accepted:
14
02
2021
pubmed:
22
2
2021
medline:
14
1
2022
entrez:
21
2
2021
Statut:
ppublish
Résumé
Vascularized composite allografts may be more susceptible to rejection than other types of organ transplants, particularly in sensitized recipients. We describe a successful transatlantic bilateral hand transplant in a 40-year old woman who was highly sensitized to class II HLA antigens including HLA-DPB1 (UNet CPRA = 86%). Prior to transplantation, we selected an upper limb donor based on HLA class II matching and absence of donor specific antibodies, given evidence that class II mismatches are associated with acute cellular rejection in hand transplants. The patient was conditioned using five doses of thymoglobulin, and her immunosuppression included tacrolimus, rapamycin, mycophenolate, and prednisone. Post-transplant, the patient non-DSA anti-HLA antibody levels drastically increased, but only transiently and weak DSAs developed, which became undetectable by two months posttransplant. Following transplantation, periodic biopsies over 6 months indicated no evidence of rejection except for transient Banff grade 1 and one sample with grade 2 acute rejection. There was no evidence of rejection on her recent 1-year follow-up. The patient is currently healthy, has recovered protective sensibility, and is regaining excellent function. This case highlights the importance of pre-transplantation planning, donor selection/compatibility, and ethical considerations in the ultimate success of VCA.
Identifiants
pubmed: 33610677
pii: S0966-3274(21)00017-4
doi: 10.1016/j.trim.2021.101377
pii:
doi:
Substances chimiques
HLA Antigens
0
Histocompatibility Antigens Class II
0
Tacrolimus
WM0HAQ4WNM
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
101377Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.